|Dr. Sharon Mates||Co-Founder, Chairman, CEO & Pres||1.33M||692k||1953|
|Mr. Lawrence J. Hineline CPA||Sr. VP of Fin., CFO, Treasurer and Assistant Sec.||645.39k||N/A||1956|
|Dr. Robert E. Davis||Sr. VP & Chief Scientific Officer||646.12k||N/A||1951|
|Mr. Michael I. Halstead J.D.||Exec. VP, Gen. Counsel & Sec.||710.78k||N/A||1973|
|Dr. Kimberly E. Vanover||Sr. VP of Early Stage Clinical Devel. & Translational Medicine||625.18k||N/A||1966|
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Intra-Cellular Therapies, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 7. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 7; Compensation: 10.